← Leaderboards
Eliezer M Van Allen
Dana-Farber Cancer Inst
$14,227,870
Attributed
$18,946,271
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.3M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,958,755 · 14
By mechanism
U2C$15,054,689 · 4
U01$7,036,007 · 2
R01$4,905,521 · 3
R37$3,212,240 · 1
P50$1,335,300 · 1
K08$708,480 · 1
Top collaborators
- Lawrence Fong5 shared
- Suzanne George4 shared
- Katherine A Janeway4 shared
- Jennifer W Mack4 shared
- Pasi A Janne2 shared
- Kent W Mouw2 shared
- Nikhil Wagle2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Hugo Aerts$3,643,476
- Jennifer W Mack$13,071,700
- Nikhil Wagle$3,389,877
- Erin M Parry$756,000
- Herve Avet Loiseau$3,475,894
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsMutationGenomicsMolecularResistanceComputational BiologyDana-Farber Cancer InstituteSomatic MutationTreatment StrategySamplingMediatingBaseCohortProgramsEventGenomePatternGenesBiologyBiologicalInvestigationAlgorithmsCancer Type
Grant awards (45)
Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults$3,418,624
U2C · FY2025 · CA
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer$725,117
R01 · FY2025 · CA · contact PI
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer$691,127
R01 · FY2025 · CA · contact PI
Dissecting and Predicting Lethal Prostate Cancer using Biologically Informed Artificial Intelligence$408,004
P50 · FY2025 · CA · contact PI
Program 09 Cancer Genetics$61,592
P30 · FY2025 · CA · contact PI
Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults$2,950,685
U2C · FY2024 · CA
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer$736,801
R01 · FY2024 · CA · contact PI
Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer$728,817
R01 · FY2024 · CA · contact PI
Dissecting and Predicting Lethal Prostate Cancer using Biologically Informed Artificial Intelligence$442,025
P50 · FY2024 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$391,555
R37 · FY2024 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$233,358
R37 · FY2024 · CA · contact PI
Program 09 Cancer Genetics$42,059
P30 · FY2024 · CA · contact PI
Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults$1,849,405
U2C · FY2023 · CA
The Cellular Geography of Therapeutic Resistance in Cancer$1,241,085
U2C · FY2023 · CA · contact PI
Dissecting and Predicting Lethal Prostate Cancer using Biologically Informed Artificial Intelligence$485,271
P50 · FY2023 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$409,863
R37 · FY2023 · CA · contact PI
Molecular Origins and Evolution to Chemoresistance in Germ Cell Tumors$153,805
R37 · FY2023 · CA · contact PI
The Cellular Geography of Therapeutic Resistance in Cancer$2,524,826
U2C · FY2022 · CA · contact PI
Count Me In: Partnering with patients to define the clinical and genomic landscape of rare aggressive sarcomas in children and adults$2,027,859
U2C · FY2022 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$844,999
U01 · FY2022 · CA · contact PI
Biospecimen Unit$607,324
U2C · FY2022 · CA · contact PI
Administrative Core$434,881
U2C · FY2022 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$407,175
R37 · FY2022 · CA · contact PI
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors$407,175
R01 · FY2022 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$845,000
U01 · FY2021 · CA · contact PI
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors$407,175
R01 · FY2021 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$407,175
R37 · FY2021 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$844,999
U01 · FY2020 · CA · contact PI
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors$407,175
R01 · FY2020 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$407,175
R37 · FY2020 · CA · contact PI
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions$193,576
R21 · FY2020 · CA · contact PI
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions$177,000
R21 · FY2020 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$842,916
U01 · FY2019 · CA · contact PI
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors$394,959
R01 · FY2019 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$394,959
R37 · FY2019 · CA · contact PI
A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions$232,291
R21 · FY2019 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$841,459
U01 · FY2018 · CA · contact PI
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors$407,175
R01 · FY2018 · CA · contact PI
Molecular origins and evolution to chemoresistance in germ cell tumors$407,175
R37 · FY2018 · CA · contact PI
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer$177,120
K08 · FY2017 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,408,317
U01 · FY2016 · HG
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer$177,120
K08 · FY2016 · CA · contact PI
The Use of Whole-Exome Sequencing to Guide the Care of Cancer Patients$1,408,317
U01 · FY2015 · HG
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer$177,120
K08 · FY2015 · CA · contact PI
Resistance to Emerging Androgen Deprivation Therapies in Prostate Cancer$177,120
K08 · FY2014 · CA · contact PI